Related Experiment Video
Updated: May 29, 2025
14:57
Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology
Published on: March 23, 2011
94.0K
Synapse vulnerability and resilience underlying Alzheimer's disease
Raquel N Taddei1, Karen E Duff2
1Neurology Department, Massachusetts General Hospital, Harvard Medical School, Boston, USA; UK Dementia Research Institute at UCL, Institute of Neurology, University College London, UK.
Ebiomedicine
|February 1, 2025
Summary
Synapse loss is a primary driver of cognitive decline in Alzheimer's disease (AD). Understanding vulnerable versus resilient synapses is crucial for developing effective AD dementia therapies and biomarkers.
Area of Science:
- Neuroscience
- Neuropathology
- Cognitive Aging
Background:
- Synapse preservation is vital for cognitive health during aging.
- Synapse loss is a critical factor in Alzheimer's disease (AD) cognitive dysfunction, preceding neuronal loss and brain atrophy.
- Synapses are early targets of AD neuropathology, making them clinically significant.
Purpose of the Study:
- To elucidate the anatomical and molecular characteristics of vulnerable and resilient synapses in AD.
- To understand the association between specific synapse populations and AD neuropathologic changes (amyloid-β plaques, tau tangles).
- To explore the relationship between synapse characteristics and memory dysfunction in AD.
Main Methods:
- The study focuses on characterizing synapse populations in the context of AD neuropathology.
- Investigating the association between synapse vulnerability/resilience and AD hallmarks.
- Analyzing the link between synapse characteristics and cognitive deficits.
Main Results:
- Synapse loss in AD is selective, affecting vulnerable synapses while sparing resilient ones.
- The specific features of vulnerable and resilient synapses in AD are not fully understood.
- The relationship between synapse populations, AD pathology, and memory impairment requires further investigation.
Conclusions:
- Characterizing selectively vulnerable and resilient synapses in AD is essential for understanding cognitive preservation and loss.
- Identifying these synapse types may lead to the development of novel biomarkers for AD dementia.
- This research could pave the way for new disease-modifying therapies targeting synapses in AD.
Related Concept Videos
01:26Alzheimer's Disease: Overview
437
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
437
01:03Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
01:23Role of Neurotransmitters in Memory
399
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
399
03:03Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
01:22Alzheimer's Disease: Treatment
158
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
158
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
393
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
393